MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
32.40
+1.92
+6.30%
After Hours: 32.41 +0.01 +0.02% 18:18 02/06 EST
OPEN
31.70
PREV CLOSE
30.48
HIGH
33.48
LOW
31.06
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
38.69
52 WEEK LOW
5.35
MARKET CAP
1.85B
P/E (TTM)
49.09
1D
5D
1M
3M
1Y
5Y
1D
Stoke Therapeutics initiated with a Buy at Guggenheim
TipRanks · 2d ago
Stoke Therapeutics präsentiert auf dem Guggenheim Emerging Outlook: Biotech Summit
Reuters · 3d ago
Stoke Therapeutics CEO to Present at Guggenheim Emerging Outlook Biotech Summit
Reuters · 3d ago
Weekly Report: what happened at STOK last week (0126-0130)?
Weekly Report · 5d ago
Will Stoke’s New Waltham Headquarters for Zorevunersen Commercialization Shift Stoke Therapeutics' (STOK) Narrative?
Simply Wall St · 5d ago
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options
NASDAQ · 01/30 16:43
A Look At Stoke Therapeutics (STOK) Valuation As New Waltham Headquarters Signals Growth Plans
Simply Wall St · 01/30 09:28
Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham
Reuters · 01/27 19:06
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.